The Problem: Diagnostics Haven't Kept Pace With Therapeutics
While drug development has embraced molecular targeting and personalized therapy, diagnostics often lag behind — relying on single-biomarker tests that fail to capture the biological complexity of treatment response. Digital pathology generates gigapixel images that overwhelm manual analysis. Wearable sensor data streams remain largely untapped for clinical decision-making. The gap between therapeutic ambition and diagnostic capability is widening.
The Solution: AI Across the Diagnostics Spectrum
AI is transforming diagnostics on three fronts: Companion diagnostics using ML-based multi-analyte signatures that predict treatment response more accurately than single-biomarker tests. Digital pathology with computer vision achieving 95%+ concordance with expert pathologists while reducing review time by 40%. Digital health applying AI to continuous wearable data for early detection of disease deterioration and adverse events.
The Approach: Regulatory-First Development
- 30-50% improvement in diagnostic sensitivity for rare conditions
- Earlier detection of treatment-related adverse events via wearable monitoring
- CE-IVD marking pathways for EU deployment under IVDR
- Swissmedic alignment through parallel assessment pathways
How ANG Associates Can Help
ANG Associates supports diagnostics companies navigating the intersection of AI innovation and regulatory compliance. We help design AI development programs with IVDR and Swissmedic requirements built in from the start, manage the complex IT infrastructure needed for digital pathology and wearable data platforms, and provide project management for cross-functional programs spanning R&D, regulatory, and commercial launch preparation.